{
    "clinical_study": {
        "@rank": "154971", 
        "brief_summary": {
            "textblock": "The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an\n      investigational monoclonal antibody administered as a first-line therapy to patients with\n      acute, Grade II, III, or IV graft-versus-host disease (GVHD).  Patients will be eligible for\n      enrollment within 24 hours of beginning standard steroid treatment.  The research is being\n      conducted at up to 10 clinical research sites in the US."
        }, 
        "brief_title": "Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease", 
        "completion_date": {
            "#text": "August 2006", 
            "@type": "Actual"
        }, 
        "condition": "Graft vs Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "A Phase I/II, open-label, dose-escalation pilot study designed to obtain preliminary safety,\n      pharmacokinetic (PK) and efficacy information on visilizumab administered as a first-line\n      therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). It is\n      anticipated that up to 34 patients at up to 10 study centers could be eligible for\n      enrollment in this study. Patients will be eligible for enrollment within 24 hours of\n      beginning standard steroid treatment (2 mg/kg of methylprednisolone IV, or 10 mg/kg\n      hydrocortisone IV, per day). Steroids will be rapidly tapered over one week following\n      visilizumab administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patients who develop Grade II, III, or IV acute GVHD following allogeneic\n             hematopoietic cell transplantation\n\n          -  Patients receiving GVHD prophylaxis including cyclosporine or tacrolimus\n\n          -  Clinical findings: skin thickening, joint contraction, oral ulceration, diarrhea.\n\n          -  Patients with an onset date of acute GVHD that is less than or equal to 100 days\n             posttransplant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "34", 
        "firstreceived_date": "March 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00032292", 
            "org_study_id": "291-405"
        }, 
        "intervention": {
            "intervention_name": "Visilizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 9, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91910"
                    }, 
                    "name": "City of Hope National Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5623"
                    }, 
                    "name": "Stanford University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232-6310"
                    }, 
                    "name": "Vanderbilt University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2006", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00032292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Facet Biotech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Facet Biotech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "City of Hope National Medical Center": "34.139 -117.977", 
        "Duke University": "35.994 -78.899", 
        "Fred Hutchinson Cancer Research Center": "47.606 -122.332", 
        "MD Anderson Cancer Center": "29.76 -95.369", 
        "Stanford University Medical Center": "37.429 -122.169", 
        "Vanderbilt University Medical Center": "36.166 -86.784", 
        "Washington University School of Medicine": "38.627 -90.199"
    }
}